我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

慢性心力衰竭伴铁缺乏患者静脉补充铁剂有效性和安全性的meta分析

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第3期
页码:
303-308
栏目:
临床研究
出版日期:
2018-03-25

文章信息/Info

Title:
Effects and safety of intravenous iron therapy in chronic heart failure with iron deficiency patients:a meta-analysis
作者:
王文晓1; 2; 杨 贤1; 方 芸1
（1.南京大学医学院附属鼓楼医院药学部，江苏 南京 210008；2.中国药科大学基础医学与临床药学学院，江苏 南京 210009）
Author(s):
WANG Wen-xiao1; 2;  YANG Xian1;  FANG Yun1
(1.Department of Pharmacy, Gulow Hospital Affiliated to Medical College of Nanjing University, Nanjing 210008, Jiangsu, China; 2.College of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu, China)
关键词:
心力衰竭; 慢性; 铁缺乏; 静脉补充铁剂; 荟萃分析
Keywords:
chronic heart failure;  iron deficiency;  intravenous iron therapy;  meta-analysis
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的 用meta分析的方法评价慢性心力衰竭伴铁缺乏患者静脉补充铁剂的有效性和安全性。方法 收集国内外关于慢性心力衰竭伴铁缺乏患者静脉补充铁剂的随机对照临床试验（RCT），按照纳入与排除标准筛选文献，评价文献质量并提取有效数据，对其有效性和安全性进行meta分析。结果 共纳入相关英文研究5篇，其方法学质量较高，2篇文献的质量等级为A级，余为B级。Meta分析结果显示:①有效性：静脉注射铁剂能够改善患者血清铁蛋白［SMD=2.15，95%CI(0.84,3.45),P<0.01］、TSAT［MD=7.97,95%CI(5.71,10.23),P<0.01］、NYHA［MD=-0.56,95%CI(-0.97,-0.15),P<0.01］，减少因心力衰竭住院的人数［OR=0.27,95%CI(0.15,0.47),P<0.01］，但不能降低全因病死率［OR=0.83,95%CI(0.43,1.60),P>0.05］；②安全性：静脉注射铁剂未增加胃肠道不良反应［OR=1.11,95%CI(0.36,3.47),P>0.05］和总不良反应［OR=0.81,95%CI(0.26,2.46),P>0.05］。结论 静脉补充铁剂能够改善慢性心力衰竭伴铁缺乏患者的心衰症状，并具有良好的安全性，但不能改善临床预后。
Abstract:
AIM To review the effects and safety of intravenous iron therapy in chronic heart failure with iron deficiency patients. METHODS Related randomized controlled clinical trials (RCTs) related to intravenous iron therapy in chronic heart failure with iron deficiency patients were collected and selected according to inclusion and exclusion criteria. The effects and safety of intravenous iron were compared with meta-analysis. RESULTS The present investigation included a total of five trials. The quality of the included studies was high. The grade of two studies was A, and three studies were evaluated as B. Meta analysis showed that intravenous iron therapy can improve serum ferritin ［SMD=2.15, 95%CI(0.84,3.45), P=0.001］, TSAT ［MD=7.97, 95%CI(5.71,10.23), P<0.01］ and NYHA ［MD=-0.56, 95%CI(-0.97, -0.15), P<0.01］, reduce the numbers of hospitalizations for heart failure［OR=0.27,95%CI(0.15, 0.47), P<0.01］, but can not reduce all-cause mortality ［OR=0.83, 95%CI(0.43,1.60), P>0.05］. Intravenous iron therapy did not increase gastrointestinal adverse events ［OR=1.11, 95%CI(0.36, 3.47), P>0.05］ or drug-related adverse events ［OR=0.81, 95%CI(0.26,2.46), P>0.05］. CONCLUSION Intravenous iron therapy in chronic heart failure with iron-deficient patients is both effective in improving symptoms of heart failure and safe, but does not significantly improve clinical prognosis.

参考文献/References

[1]Klip IT,Comin-Colet J,Voors AA,et al.Iron deficiency in chronic heart failure:an international pooled analysis[J].Am Heart J,2013,165(4):575-582.

[2]Hamaguchi S,Tsuchihashi-Makaya M,Kinugawa S,et al.Anemiais an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan.A report from the Japanese Cardiac Registry of Heart Failure in Cardiology(JCARE-CARD)[J].Circ J,2009,73(10):1901-1908.

[3]Drozd M,Jankowska EA,Banasiak W,et al.Iron Therapy in Patients with Heart Failure and Iron Deficiency:Review of Iron Preparations for Practitioners[J].Am J Cardiovasc Drugs,2017,17(3):183-201.

[4]Anand I,McMurray JJ,Whitmore J,et al.Anemia and its relationship to clinical outcome in heart failure[J].Circulation,2004,110(2):149-154.

[5]Nu?n?ez J,Comín-Colet J,Min?ana G,et al.Iron deficiency and risk of early readmission following a hospitalization for acute heart failure[J].Eur J Heart Fail,2016,18(7):798-802.

[6]Jankowska EA,Rozentryt P,Witkowska A,et al.Iron defi- ciency: an ominous sign in patients with systolic chronic heart failure[J].Eur Heart J,2010,31(15):1872-1880.

[7]周京敏,崔 洁.铁缺乏症是慢性心力衰竭治疗的新目标[J].岭南心血管病杂志,2015,21(1):7-10.

[8]von Haehling S,Gremmler U,Krumm M,et al.Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure:The PrEP Registry[J].Clin Res Cardiol,2017,106(6):436-443.

[9]Toblli JE,Di Gennaro F,Rivas C,et al.Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron[J].Heart Lung Circ,2015,24(7):686-695.

[10]Ponikowski P,van Veldhuisen DJ,Comin-Colet J,et al.Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency[J].Eur Heart J,2015,36(11):657-668.

[11]Anker SD,Comin Colet J,Filippatos G,et al.Ferric carboxymaltosein patients withheart failureandirondeficiency[J].N Engl J Med,2009,361(25):2436-2448.

[12]Okonko DO,Grzeslo A,Witkowski T,et al.Effect of intravenousiron sucroseon exercise tolerance in anemic and nonanemic patients with symptomatic chronicheart failureandirondeficiency FERRIC-HF: a randomized, controlled,observer-blinded trial[J].J Am Coll Cardiol,2008,51(2):103-112.

[13]Beck-da-Silva L,Piardi D,Soder S,et al.IRON-HFstudy:a randomized trial to assess the effects of iron in heart failure patients with anemia[J].Int J Cardiol,2013,168(4):3439-3442.

[14]Toblli JE,Lombra?a A,Duarte P,et al.Intravenousironreduces NT-pro-brain natriuretic peptide in anemic patients with chronicheart failureand renal insufficiency[J].J Am Coll Cardiol,2007,50(17):1657-1665.

[15]Avni T,Leibovici L,Gafter-Gvili A.Iron supplementation for the treatment of chronic heart failure and iron deficiency:systematic review and meta-analysis[J].Eur J Heart Fail,2012,14(4):423-429.

[16]Jankowska,Micha? Tkaczyszyn,Tomasz Suchocki,et al.Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure:a meta-analysis of randomized controlled trials[J].Eur J Heart Fail,2016,18(7):786-795.

[17]Atherton JJ,Hayward CS,Wan Ahmad WA,et al.Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific(ADHERE International-Asia Pacific)[J].Card Fail,2012,18(1):82-88.

[18]Yeo TJ,Yeo PS,Hadi FA,et al.Rationale and design of a pilot randomized controlled trial to assess the role of intravenousferric carboxymaltosein Asian patients withheart failure(PRACTICE-ASIA-HF)[J].ESC Heart Fail,2016,3(2):71-76.

备注/Memo

备注/Memo:
收稿日期：2017-05-04.通讯作者：方芸，主任药师，主要从事临床药学研究 Email：njglfy@163.com 作者简介：王文晓，硕士生 Email：Moshengren829@126.com
更新日期/Last Update: 1900-01-01